Discontinue at onset of pulmonary signs eg, cough, fever & dyspnoea in association w/ radiological signs of pulmonary infiltrates & deterioration in pulmonary function along w/ increased neutrophil count; if leukocyte counts exceed 50 x 10
9/L after expected nadir occurs. Permanently discontinue in patients w/ clinically significant hypersensitivity. Not to be used to increase dose of cytotoxic chemotherapy beyond established dose regimens. Not to be administered in patients w/ history of hypersensitivity to pegfilgrastim or filgrastim. Not to be restarted if patient has developed SJS. Closely monitor & standard symptomatic treatment including need for intensive care if capillary leak syndrome develops characterized by hypotension, hypoalbuminaemia, oedema & hemoconcentration. Evaluate patients w/ left upper abdominal &/or shoulder tip pain for enlarged spleen or splenic rupture. Increased risk of neutropenia, febrile neutropenia &/or infection if medication error eg, partial or missed dose occurs. Increased hematopoietic activity of bone marrow in response to growth factor therapy. Patients w/
de novo AML; myelodysplastic syndrome, chronic myelogenous leukemia & secondary AML; sickle cell trait or sickle cell disease. Glomerulonephritis; aortitis symptoms including fever, abdominal & back pain, malaise & increased inflammatory markers (eg, C-reactive protein & WBC count). Potential for immunogenicity. Carefully monitor spleen size. Regularly monitor platelet count & haematocrit. Perform WBC count at regular intervals during therapy. Fructose intolerance. Not to be used during pregnancy & lactation. Childn & adolescents <18 yr. AML patients <55 yr w/ cytogenetics.
Sign Out
